Brought to you by 
Takeda acquires Syrrx
Feb 2005
Executive Summary
Takeda Pharmaceuticals, Japan's largest drug maker, has agreed to acquire privately held Syrrx Inc. (US; structure-based drug design for metabolic diseases, inflammation, and cancer) for $270mm in cash.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Acquisition of Private Biotech
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda acquires Syrrx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice